Article

Calcitriol-chemo combo improves prostate cancer survival

Paris--Adding a form of high-dose calcitriol to docetaxel (Taxotere) offers improved survival over docetaxel alone in men with metastatic androgen-independent prostate cancer, according to results of a multicenter trial presented at the 13th European Cancer Conference (ECCO-13) here. Further, the addition of the calcitriol formulation, known as DN-101, to the chemotherapy agent produced an unanticipated advantage in a reduced number of serious gastrointestinal and thromboembolic adverse events.

Paris-Adding a form of high-dose calcitriol to docetaxel (Taxotere) offers improved survival over docetaxel alone in men with metastatic androgen-independent prostate cancer, according to results of a multicenter trial presented at the 13th European Cancer Conference (ECCO-13) here. Further, the addition of the calcitriol formulation, known as DN-101, to the chemotherapy agent produced an unanticipated advantage in a reduced number of serious gastrointestinal and thromboembolic adverse events.

"DN-101 has a unique safety profile, and it appears to improve the toxicity of docetaxel. We need confirmatory evidence," said Tomasz Beer, MD, director of the Prostate Cancer Program, Oregon Health & Science University Cancer Institute, Portland, and lead investigator of the double-blind, randomized Androgen-Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere (ASCENT).

A confirmatory trial is planned for this year to compare DN-101 plus docetaxel versus docetaxel plus prednisone. ASCENT-2, the phase III trial, will have survival as the primary endpoint. Enrollment is scheduled to begin in first-quarter 2006.

Epidemiologic data link vitamin D deficiency to a variety of tumor types, including prostate cancer. Preliminary studies found that high-dose calcitriol, a naturally occurring hormone and vitamin D receptor ligand, showed promising activity in prostate cancer by enhancing the action of chemotherapeutic agents in producing anti-tumor activity. A similar effect has not been seen with low-dose calcitriol.

ASCENT randomized 250 patients with previously untreated metastatic androgen-independent prostate cancer to weekly treatments with docetaxel, 36 mg/m2 , given intravenously for 3 weeks of a 4-week cycle. They received either DN-101, 45 µg, or placebo 1 day prior to their docetaxel treatment, and all received ongoing androgen deprivation therapy.

At median follow-up of 18.3 months, 229 patients (92%) were off treatment. One-half of all patients (49%) died. No significant difference between treatment arms was observed for PSA response at 6 months: PSA response was 49% in the docetaxel/placebo arm versus 58% in the docetaxel/DN-101 arm.

Median survival was 16.4 months in the placebo arm and has not been reached, but is estimated at 24.5 months in the DN-101 arm. Multivariate analysis showed that duration of survival was improved in patients who received DN-101 (HR, .67; p=.035). Median survival has been reached in the placebo arm, but it has not yet been attained in the DN-101 arm.

Other endpoints favoring DN-101 included the number of patients who had a 50% reduction in PSA at 6 months, time to PSA response, skeletal morbidity-free survival, and tumor response rates.

Exploratory analysis revealed an unanticipated favorable effect of DN-101 on serious adverse events, Dr. Beer said. Serious adverse events at a median of 18.3 months were reported in 41% of the placebo group and 27% of the DN-101 group (p=.023); grade 3 or 4 adverse events occurred in 70% and 58% of patients, respectively.

Dr. Beer said a possible explanation for this effect was that vitamin D receptor ligands decrease tissue factor expression and increase expression of thrombomodulin a protein that activates protein C, an endogenous anticoagulant. In addition, the ligands have been shown to reduce proliferation of epithelial cells in the gastrointestinal tract.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

© 2025 MJH Life Sciences

All rights reserved.